Oligonucleotide therapies for modulating the effects of herpes v

Chemistry: molecular biology and microbiology – Virus or bacteriophage – except for viral vector or... – Inactivation or attenuation; producing viral subunits

Patent

Rate now

  [ 0.00 ] – not rated yet Voters 0   Comments 0

Details

536 231, 536 245, 514 44, 4352402, 935 34, C12N 706, C07H 2104

Patent

active

055145779

ABSTRACT:
Compositions and methods are provided for the treatment and diagnosis of herpesvirus infections. In accordance with preferred embodiments, oligonucleotides are provided which are specifically hybridizable with RNA or DNA deriving from a herpesvirus gene corresponding to one of the open reading frames UL5, UL8, UL9, UL20, UL27, UL29, UL30, UL42, UL52 and IE175 of herpes simplex virus type 1. The oligonucleotide comprises nucleotide units sufficient in identity and number to effect said specific hybridization. In other preferred embodiments, the oligonucleotides are specifically hybridizable with a translation initiation site, a coding region or a 5'-untranslated region. Methods of treating animals suspected of being infected with herpesvirus comprising contacting the animal with an oligonucleotide of the invention are disclosed. Methods for treatment of infections caused by herpes simplex virus type 1, herpes simplex virus type 2, cytomegalovirus, human herpes virus 6, Epstein Barr virus or varicella zoster virus are disclosed.

REFERENCES:
patent: 4689320 (1987-08-01), Kaji
patent: 5034506 (1991-07-01), Summerton
R N Ryan et al (1986) Microbiology 1986, Washington D.C., pp. 113-116.
R Weiss (1991) Science News 139: 108-109.
E Uhlmann et al (1990) Chemical Reviews 90(4): 569-571.
E R Kern (1990) Antiviral Agents and Viral Diseases of Man, Galasso et al, eds, pp. 94-95.
McGeoch, D. J., et al., "Complete DNA Sequence of the short repeat region in the genome of herpes simplex virus type 1," Nucleic Acids Res. 14:1727-1745, 1986.
McGeoch, D. J., et al., "The Complete DNA Sequence of the Long Unique Region in the Genome of Herpes Simplex Virus Type 1," J. Gen. Virol. 69:1531-1574, 1988.
Perry, L. J. and McGeoch, D. J., "The DNA Sequences of the Long Repeat Region and Adjoining Parts of the Long Unique Region in the Genome of Herpes Simplex Virus Type 1," J. Gen. Virol. 69:2831-2846, 1988.
Blair, E. D., et al., "Herpes Simplex Virus Virion Stimulatory Protein mRNA Leader Contains Sequence Elements Which Increase Both Virus-Induced Transcription and mRNA Stability," J. Virol. 61:2499-2508, 1987.
Ceruzzi, M, and Draper, K., "The Intracellular and Extracellular Fate of Oligodeoxyribonucleotides in Tissue Culture Systems," Nucleosides and Nucleotides 8:815-818, 1989.
Mossmann, T., J. Immunol. Methods. 65:55, 1983.
Cai, W., et al. J. Virol. 62:2596-2604, 1988.
Kulka, M., et al., "Site specificity of the inhibitory effects of oligo (nucleoside methylphosphonate)s complementary to the acceptor splice junction of herpes simplex virus type 1 immediate early mRNA4," Proc. Natl. Acad. Sci. USA 86:6868-6872, 1989.
Smith, C. C., et al, "Antiviral effect of an oligo (nucleoside methylphosphonate) complementary to the splice junction of herpes simplex virus type 1 immediate early pre-mRNAs 4 and 5," Proc. Natl. Acad. Sci. USA 83:2787-2792, 1986.
Davison, A. J. & Scott, J. E., "The Complete DNA Sequence of Varicella-Zoster Virus," J. Gen. Virol. 67:1759-1816, 1987.
Baer, R., et al, "DNA sequence and expression of the B95-8 Epstein-Barr virus genome," Nature 310:207-211, 1984.
Davison, A. J. and McGeoch, D. J., J. Gen Virol. 67:597-611, 1986.
Davison, A. J. and Wilkie, N. M. J. Gen. Virol. 64:1927-1942, 1983.
P. E. Nielsen, et al. "Sequence-Selective Recognition of DNA by Strand Displacement with a Thymine-Substituted Polyamide," Science 254:1497, 1991.
McGeoch, D. J., et al., "Sequence Determination and Genetic Content of the Short Unique Region in the Genome of Herpes Simplex Virus Type 1," J. Mol. Biol. 181:1-13, 1985.

LandOfFree

Say what you really think

Search LandOfFree.com for the USA inventors and patents. Rate them and share your experience with other people.

Rating

Oligonucleotide therapies for modulating the effects of herpes v does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Oligonucleotide therapies for modulating the effects of herpes v, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Oligonucleotide therapies for modulating the effects of herpes v will most certainly appreciate the feedback.

Rate now

     

Profile ID: LFUS-PAI-O-1226658

  Search
All data on this website is collected from public sources. Our data reflects the most accurate information available at the time of publication.